Abstract
Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavours, with low response rates and survival rarely exceeding 6 months. There are no standard chemotherapeutic regimens and new therapeutic approaches have to be found. We report an open-label, uncontrolled, multicentre phase II trial of lonidamine (LND) and diazepam in 16 patients with GBM at first relapse and a Karnofsky performance status ≥70. The treatment regimen consisted of LND 450 mg/day and diazepam 15 mg/day orally of every 28-day cycle until progression or unacceptable toxicity. Patients received a median of three cycles (range, 1–12). No complete or partial response was observed. Therefore, according to the design of the study, no additional patients were enrolled and the trial was closed. Nevertheless, seven stabilizations (50%) were observed. Median time to progression was 8 weeks (range, 5–19 weeks). Median overall survival from recurrence was 15 weeks (range, 14–61 weeks). No grade 3–4 toxicity, except somnolence, was observed and there were no therapy-related deaths. Dose reduction for diazepam due to somnolence (grade III) was performed in 9 patients. The combination of LND and diazepam is well tolerated. LND and diazepam, acting on two distinct mitochondrial sites involved in cellular energy metabolism, may exert a cytostatic effect on tumour growth as shown by the high percentage of stable patients. The LND–diazepam at the used dosing schedule did not show a complete or partial response. LND plus diazepam may be interesting in the adjuvant setting or associated to chemotherapy to act on different targets and increase the therapeutic index.
Similar content being viewed by others
References
Delattre JY, Uchuya M: Radiotherapy and chemotherapy for gliomas. Curr Opin Oncol 8: 196-203, 1996
Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956
Nakashima RA, Mangan PS, Colombini M, Pedersen PL: Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N?-dicyclohexylcarbodiimide-labelling studies for the involvement of the pore-forming protein VDAC. Biochemistry 25: 1015-1021, 1986
Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, Poisson M, Dutrillaux B, Poupon MF: High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 74: 839-845, 1996
Bigner SH, Mark J, Bigner DD: Cytogenetics of human brain tumours. Cancer Genet Cytogenet 47: 141-154, 1990
Linden M, Gellerfors P, Nelson BD: Pore protein and the hexokinase-binding protein from the outer membrane of rat liver mitochondria are identical. FEBS Lett 14: 189-192, 1982
Miettinen H, Kononen J, Haapasalo H, Helen P, Sallinen P, Harjuntausta T, Helin H, Alho H: Expression of peripheral-type benzodiazepine receptor and diazepambinding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 55: 2691-2695, 1995
Wang JKT, Morgan JI, Spector S: Differentiation of Friend erythroleukemia cells induced by benzodiazepines.Proc Natl Acad Sci USA 81: 3770-3772, 1984
Wang JKT, Morgan JI, Spector S: Benzodiazepines that bind at peripheral sites inhibits cell proliferation. Proc Natl Acad Sci USA 81: 753-756, 1984
Carayon P, Portier M, Dussossoy D, Bord A, Petitpretre G, Canat X, Le Fur G, Casellas P: Involvement of peripheral benzodiazepine receptors in the protection of haematopoietic cells against oxygen radical damage. Blood 87: 3170-3178, 1996
Miccoli L, Poirson-Bichat F, Sureau F, Bras Goncalves R, Bourgeois Y, Dutrillaux B, Poupon MF, Oudard S: Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 18: 1400-1406, 1998
Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumour cells. Cancer Res 41: 4661-4666, 1981
Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B, Poupon MF: Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62: 216-222, 1995
Carapella CM, Paggi MG, Cattani F, Ciottoli GB, Floridi A, Iandolo B, Raus L, Riccio A, Caputo A: The potential role of lonidamine in the treatment of malignant gliomas; a phase II study. J Neuro-Oncol 7: 103-108, 1989
Braestrup C, Squires RF: Specific benzodiazepine receptors in rat brain characterized by high-affinity [3H]diazepam binding. Proc Natl Acad Sci USA 74: 3805-3809, 1997
Floridi A, Lehninger AL: Action of the antitumour and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys 226: 73-83, 1983
Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G: Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18: 2537-2546, 1999
Beurdeley-Thomas A, Miccoli L, Oudard S, Dutrillaux B, Poupon MF: The peripheral benzodiazepine receptors: a review. J Neuro-Oncol 46: 45-56, 2000
Carapella CM, Paggi MG, Calvosa F, Cattani F, Jandolo B, Mastrostefano R, Raus L, Riccio A: Lonidamine in the combined treatment of malignant gliomas. J Neurosurg Sci 34: 261-264, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oudard, S., Carpentier, A., Banu, E. et al. Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme. J Neurooncol 63, 81–86 (2003). https://doi.org/10.1023/A:1023756707900
Issue Date:
DOI: https://doi.org/10.1023/A:1023756707900